Navigation Links
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/14/2009

pproximately $4.47 million, compared to approximately $6.39 million for the same period in 2008. The $1.92 million decrease is primarily attributable to lower Intermezzo(R) development costs, the majority of which were incurred prior to the submission of the Intermezzo(R) NDA on September 30, 2008. Research and development expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $157,000 for the six months ended June 30, 2009 and $130,000 for the six months ended June 30, 2008.

General and administrative expenses for the six months ended June 30, 2009 were approximately $9.23 million, compared to approximately $3.22 million for the same period in 2008. The $6.01 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration, increased marketing expenses as we prepared to commercialize Intermezzo(R) and an increase in operational expenses associated with the addition of the Novacea office space in South San Francisco.

General and administrative expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $394,000 for the six months ended June 30, 2009, as compared to $162,000 for the six months ended June 30, 2008.

Year-to-date merger-related transaction costs of approximately $2.22 million were expensed during the first quarter of 2009.

Net loss for the six months ended June 30, 2009 was approximately $15.7 million or $1.42 per share, compared to a net loss of approximately $9.6 million or $26.16 per share for the six months ended June 30, 2008. The weighted average common shares used to calculate earnings per share were 11,047,881 and 366,226 respectively for the six months ended June 30, 2009 and 2008.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
2. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
3. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
4. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
6. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
7. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
9. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
10. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
11. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... prevalence of preterm birth the birth of an ... a significant health problem that has increased over the ... Disease Control and Prevention (CDC), preterm birth affects nearly ... born in the U.S. While medical care has improved ... to positively impact the neurodevelopmental outcomes of preterm infants. ...
(Date:9/21/2014)... 2014 AstraZeneca’s Pulmicort is an ... and is used prophylactically for the maintenance treatment ... ingredient, budesonide, is an anti-inflammatory corticosteroid with a ... franchise includes the Pulmicort Flexhaler (budesonide) for adults ... age, Pulmicort Respules for children between one and ...
(Date:9/21/2014)... (PRWEB) September 22, 2014 PhUSE is ... and Dr. Lilliam Rosario as keynote speakers for their ... keynotes from Dr. Ben Goldacre in 2013 , ... Lord Winston in 2011 , PhUSE again presents high-calibre ... are passionate about advancement of clinical information. , Dr. ...
(Date:9/21/2014)... The Laboratory Testing Services industry is composed ... on items ranging from consumer and food products to ... operators to ensure the safety and quality of their ... government safety regulations and consumer lawsuits have led to ... revenue briefly dipped in 2009 as the US economy ...
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... moderate exercise has positive benefits on the hearts, holding ... in the last 10 to 20 years have shown ... suffering from congestive heart failure. ,However, the positive ... be statistically significant. ,In the new study rats ...
... of 62-year-old Moira Pullar on 17 January 2004 at Monklands ... who failed to cross check// the records in the hospital, ... bronchial pneumonia after cardiac arrest and brain damage. ... leading to the fatal dose. The warning signs of the ...
... The increasing number of people resorting to sleeping pills for ... more effective medications. However, they may not have the best ... ,The importance of sleep can be inferred form ... man healthy, wealthy and wise’. For those of them who ...
... in a panic after news that HIV infected blood had ... infected with the virus. A 35 year old female donor ... Conflicting statements are coming in from the authorities with regard ... blood. ,Russia faces the most serious HIV/AIDS problem ...
... that fruitfly gut stem cells and human intestine stem cells ... of both are alike. The similarity found between stem ... mechanims of cell regulation in digestive disorders and stomach cancers ... gastrointestinal tract as vertebrates. They have a mouth, an esophagus, ...
... faces further problems as it has emerged that more and ... and do not need the support of dentures, according// to ... ,The study says that as older people retain their own ... fillings and periodontal procedures like cleaning and curettage. Additionally, they ...
Cached Medicine News:Health News:Newer Generation Sleeping Pills Lack Superior Performance 2
(Date:9/19/2014)... Sept. 19, 2014 Kiromic, LLC, a ... Kent Hance , the former chancellor of Texas Tech ... as chancellor in July 2014, after raising $1.2 billion for ... Kent Hance , the most successful chancellor in the ... not only as an investor, but also as our new ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
(Date:9/19/2014)...  Diplomat, the nation,s largest independent specialty pharmacy, has ... the Board of Directors on September 15, 2014. Mr. ... as chair of the Audit Committee. ... compliance and operating experience in the health care field.  ... financial officer, chief operating officer and secretary of Patient ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 24WEB Medical Unveils 3D-Printed Osteotomy Truss System 2David Dreyer Appointed to Diplomat Board of Directors 2
... Cempra Pharmaceuticals announced that Carl Foster has ...  Mr. Foster will be focusing on business development ... programs, the next-generation fluoroketolide solithromycin (CEM-101), that is ... pneumonia (CABP), and TAKSTATM (CEM-102 or fusidic acid), ...
... -- Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC ... it has obtained the exclusive sales rights of Thymosin ... Shanghai Biochemistry Pharmaceutical Co. I. The State ... the manufacturing permit of Thymosin Alpha 1 Injection for ...
Cached Medicine Technology:Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development 2Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection 2Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection 3
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Medicine Products: